Cogent Biosciences (COGT) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Regulatory and pivotal GIST evidence
NDAs are under FDA review; PDUFA action dates are Nov. 30, 2026 for GIST, Dec. 30, 2026 for non-advanced systemic mastocytosis, and June 29, 2027 for advanced systemic mastocytosis.
In PEAK, bezuclastinib plus sunitinib showed a 0.50 hazard ratio for the primary endpoint; estimated median PFS was 16.5 months vs. just over 9 months for control, with nearly double the objective response rate.
Average treatment duration on the PEAK combination exceeded 21 months, vs. a pre-study second-line GIST expectation of 7–8 months.
GIST review is under Breakthrough Therapy Designation and Real-Time Oncology Review; management expects approval and says bezuclastinib could provide long-term benefit with sunitinib.
Safety and labeling
Across studies from 100 mg daily in non-advanced disease to 600 mg in metastatic GIST, common events include taste changes, hair depigmentation and elevated transaminases, reported as lab abnormalities.
Management reported no liver failure, transplant, serious liver clinical adverse events or Hy’s Law cases; transaminases returned to baseline with or without intervention, dose reduction or, rarely, discontinuation.
Management supports blood-lab liver monitoring; it said the final label is uncertain and FDA precedent varies on carrying combination-partner warnings into a new drug’s label.
Sunitinib, the GIST combination partner, has monthly transaminase monitoring language and a boxed hepatotoxicity warning; management sees monitoring as no barrier to prescribing or use across indications.
Launch readiness and commercial strategy
Commercial hiring is underway, with one sales force planned to cover GIST and both mastocytosis indications; shared clinical sites allow representatives to reach distinct specialist groups at the same locations.
U.S. expanded access programs are open across all three indications and have drawn strong interest; transitioning EAP patients to commercial treatment is an early launch priority after approval.
Management expects a potentially rapid GIST launch, citing no current second-line competition and an add-on approach to generic sunitinib; mastocytosis launch efforts will emphasize patient communication and may build more slowly.
Brand strategy was set at NDA submission and is expected to be outlined after approval; management said one or multiple brands would not dramatically change commercial ramp or uptake.
Latest events from Cogent Biosciences
- Three FDA decisions ahead; launch infrastructure is ready for near-term approvals.COGT
UBS Global Biopharma Conference 2026 - Bezuclastinib nears U.S. decisions with launch readiness and pipeline expansion underway.COGT
3rd Annual Guggenheim Healthcare Innovation Conference - Three bezuclastinib FDA decisions loom as $791.1M in liquidity supports launch preparations.COGT
Q3 2026 - Three NDAs pending FDA review, strong trial results, and cash runway into late 2028.COGT
Q2 2026 - Pivotal trial readouts for bezuclastinib in rare diseases and GIST expected in 2025.COGT
Guggenheim SMID Cap Biotech Conference - All proposals, including director elections and auditor ratification, were approved.COGT
AGM 2026 - Bezuclastinib plus sunitinib delivers breakthrough efficacy in GIST, with rapid adoption anticipated.COGT
Jefferies Global Healthcare Conference 2026 - Bezuclastinib's pivotal trial wins set up a transformative 2026 launch and long-term market leadership.COGT
44th Annual J.P. Morgan Healthcare Conference - Bezuclastinib delivered robust symptom and biomarker improvements with good tolerability in non-advanced SM.COGT
Study Result - Pivotal trial readouts for Bezuclastinib in SM and GIST expected in 2025, with strong market potential.COGT
Piper Sandler 36th Annual Healthcare Conference